A second, related test, called the HairDX (RxR) test, has also been developed which measures an individual’s likely response to treatment with finasteride. Combined with the test for loss, the finasteride response test could
help a man pinpoint a time at which he can begin the treatment for hair loss, and retain as much of his hair as possible, without having to undergo a re-growth period. Since, currently, the only FDA-approved treatments for
hair loss are best at preserving the hair, being able to determine a likelihood of loss, and how effective the treatment will be for an individual are invaluable. Together, these tests can help an individual make a more
informed decision and get better results from hair loss treatment.
A Bonus Benefit
The HairDX (RxR) test provides men with a CAG repeat score (like the one provided to women in the HairDX test). For men, the CAG repeat score is associated with an increased response to finasteride treatments. In addition,
smaller CAG scores are associated with risk of developing a condition called Benign Prostatic Hyperplasia (or Enlarged Prostate).
Since an enlarged prostate can also lead to other problems – including urinary difficulties and sexual dysfunction – early warning is important. The takes on added importance when it is combined with the knowledge that
another problem associated with enlarged prostate is the increased likelihood of undetected prostate tumors as a result of the enlarged prostate.
The company responsible for creating these tests is PharmaGenoma, Inc., a dermatology company founded in 2007 by leading researches and specialists in genetics and dermatology. The company is dedicated to the research and
development of new prescription therapies for skin conditions tailored to the genetic make-up of an individual.
Currently, the test’s cost varies by the area in which you live but is less than $200 (U.S. Dollars). The test kit for male and female pattern baldness is listed with the U.S. FDA as a Class 1 medical device.